Inhibikase Therapeutics (IKT)
(Delayed Data from NSDQ)
$1.89 USD
+0.03 (1.61%)
Updated May 21, 2024 03:59 PM ET
After-Market: $1.89 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IKT 1.89 +0.03(1.61%)
Will IKT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IKT
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
New Strong Buy Stocks for February 13th
IKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for February 8th
New Strong Buy Stocks for February 8th
New Strong Buy Stocks for February 6th
Other News for IKT
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics price target lowered by $4 at H.C. Wainwright, here's why
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
Inhibikase Therapeutics prices its direct offering, warrant inducement
Inhibikase announces pricing of registered direct offering, warrant inducement